New Research Advances on Chimeric Antigen Receptor T Cells in the Treatment of Relapsed and Refractory Multiple Myeloma-Review.
10.19746/j.cnki.issn.1009-2137.2019.04.053
- Author:
Fang-Rong ZHANG
1
;
Xin LI
1
;
Jing LIU
2
Author Information
1. Department of Hematology, Xiangya Third Hospital, Central South University, Changsha 410013，Hunan Province，China.
2. Department of Hematology, Xiangya Third Hospital, Central South University, Changsha 410013，Hunan Province，China,E-mail: jingliu0318@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Immunotherapy, Adoptive;
Multiple Myeloma;
Receptors, Antigen, T-Cell;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Journal of Experimental Hematology
2019;27(4):1316-1320
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Chimeric antigen receptor-T cell(CAR-T) is a kind of genetically engineered T cells that can express tumor antigen-specific receptors on its surface, and the modified T cells can be used for cancer therapy through targeting malignant tumor cells with its specific receptor and killing tumor cells with its cytotoxicity. CAR-T has been successfully applied to treat various hematological malignancies, such as ALL, CLL, NHL and MM. It is a feasible treatment for relapsed and refractory multiple myeloma (RRMM). The achievements of CAR-T in clinical trials have been widely reported, which is expected to be a therapy to prolong patients survival. In this review, the clinical application of CAR-T in the treatment of RRMM from the following aspects：different types of CAR-T and its curative efficacy, adverse effects, opportunities and challenges are summarized beriefly.
